• Mr. Ghumare Vaibhav
• Mr. Lahu Hingane
• Mr. Mhaske Mahesh
• Mr. Dhonde Pritam

Cariprazine is an antipsychotic medication and received approval by the U.S. Food and Drug Administration for the treatment of schizophrenia in September 2015. Cariprazine is a dopamine D3 and D2 receptor partial agonist, with a preference for the D3 receptor. Cariprazine is also a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors. This comprehensive review of cariprazine summarizes its pharmacologic profile, clinical trial evidence, and post hoc investigations. Collective evidence suggests that the pharmacology of cariprazine may offer broad-spectrum efficacy advantages for patients with schizophrenia, including effects against difficult- to-treat negative and cognitive symptoms, as well as functional improvements.

Cariprazine, Drug Interaction, Pharmacokinetics.

"A REVIEW ON CARIPRAZINE AS AN ANTIPSYCHOTIC DRUG", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 7, page no.a443-a449, July-2022, Available :http://www.jetir.org/papers/JETIR2207053.pdf

"A REVIEW ON CARIPRAZINE AS AN ANTIPSYCHOTIC DRUG", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 7, page no. ppa443-a449, July-2022, Available at : http://www.jetir.org/papers/JETIR2207053.pdf